This paper seeks to provide an economic perspective on the pharmaceutical i
ndustry, which has come under increasing criticism on a number of issues. I
n the main, that criticism amounts to a rather ineffective flailing at the
supply side of the market for pharmaceutical products-much of it based on i
naccurate perceptions-when a more productive policy would be to strengthen
the hitherto weak and poorly informed demand side of the market.